New hope for recurrent brain cancer? early trial of CUE-102 begins
Disease control
Recruiting now
This early-phase trial tests an experimental drug called CUE-102 in 18 adults with recurrent glioblastoma, a type of brain cancer that has come back. The drug is a fusion protein designed to help the immune system attack cancer cells. The main goal is to find a safe dose and chec…
Phase: PHASE1 • Sponsor: David Reardon, MD • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC